Literature DB >> 17963300

Early prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeks.

Geert Robaeys1, Jozef De Bie, Marieke C Wichers, Liesbeth Bruckers, Frederik Nevens, Peter Michielsen, Marc Van Ranst, Frank Buntinx.   

Abstract

AIM: To study the predictive value of the vegetative-depressive symptoms of the Zung Depression Rating Scale for the occurrence of depression during treatment with peg-interferon alpha-2b of chronic hepatitis C (CHC) patients.
METHODS: The predictive value of vegetative-depressive symptoms at 4 wk of treatment for the occurrence of a subsequent diagnosis of major depressive disorder (MDD) was studied in CHC patients infected after substance use in a prospective, multi-center treatment trial in Belgium. The presence of vegetative-depressive symptoms was assessed using the Zung Scale before and 4 wk after the start of antiviral treatment.
RESULTS: Out of 49 eligible patients, 19 (39%) developed MDD. The area under the ROC curve of the vegetative Zung subscale was 0.73, P = 0.004. The sensitivity at a cut-point of > 15/35 was 95% (95% CI: 74-100). The positive predictive value equalled 44% (95% CI: 29-60).
CONCLUSION: In this group of Belgian CHC patients infected after substance use, antiviral treatment caused a considerable risk of depression. Seven vegetative-depressive symptoms of the Zung scale at wk 4 of treatment predicted 95% of all emerging depressions, at a price of 56% false positive test results.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17963300      PMCID: PMC4171260          DOI: 10.3748/wjg.v13.i43.5736

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes.

Authors:  Geert Robaeys; Hans Van Vlierberghe; Catharina Matheï; Marc Van Ranst; Liesbeth Bruckers; Frank Buntinx
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-02       Impact factor: 2.566

Review 2.  Hepatitis C treatment in drug users: perception versus evidence.

Authors:  Diana Sylvestre
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-02       Impact factor: 2.566

3.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

4.  Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.

Authors:  Stavroula Beratis; Aggeliki Katrivanou; Sophia Georgiou; Alexandra Monastirli; Efstathia Pasmatzi; Philippos Gourzis; Dionysios Tsambaos
Journal:  J Psychosom Res       Date:  2005-01       Impact factor: 3.006

5.  Interferon-induced depression: prevalence and management.

Authors:  A Scalori; M Pozzi; V Bellia; P Apale; G Santamaria; T Bordoni; A Redaelli; A Avolio; P Parravicini; P Pioltelli; L Roffi
Journal:  Dig Liver Dis       Date:  2005-02       Impact factor: 4.088

6.  Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.

Authors:  Naoshi Horikawa; Tomoko Yamazaki; Namiki Izumi; Masakatsu Uchihara
Journal:  Gen Hosp Psychiatry       Date:  2003 Jan-Feb       Impact factor: 3.238

7.  Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

Authors:  Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller
Journal:  Neuropsychopharmacology       Date:  2002-05       Impact factor: 7.853

8.  Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence.

Authors:  R C Kessler; K A McGonagle; M Swartz; D G Blazer; C B Nelson
Journal:  J Affect Disord       Date:  1993 Oct-Nov       Impact factor: 4.839

9.  Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.

Authors:  Martin Schaefer; Folkhard Schmidt; Christian Folwaczny; Reinhard Lorenz; Gaby Martin; Norbert Schindlbeck; Walter Heldwein; Michael Soyka; Heinz Grunze; August Koenig; Klaus Loeschke
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

10.  A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

Authors:  P Hauser; J Khosla; H Aurora; J Laurin; M A Kling; J Hill; M Gulati; A J Thornton; R L Schultz; A D Valentine; C A Meyers; C D Howell
Journal:  Mol Psychiatry       Date:  2002       Impact factor: 15.992

View more
  10 in total

Review 1.  Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?

Authors:  Donna M Evon; Carol E Golin; Michael W Fried; Francis J Keefe
Journal:  J Consult Clin Psychol       Date:  2012-06-25

2.  Feasibility and impact of a guided symptom exposure augmented cognitive behavior therapy protocol to prevent symptoms of pharmacologically induced depression: A pilot study.

Authors:  Lata K McGinn; Anna Van Meter; Ian Kronish; Jessica Gashin; Karen Burns; Natalie Kil; Thomas G McGinn
Journal:  Cognit Ther Res       Date:  2019-02-12

Review 3.  From stress to inflammation and major depressive disorder: a social signal transduction theory of depression.

Authors:  George M Slavich; Michael R Irwin
Journal:  Psychol Bull       Date:  2014-01-13       Impact factor: 17.737

Review 4.  Is depression an inflammatory disorder?

Authors:  Charles L Raison; Andrew H Miller
Journal:  Curr Psychiatry Rep       Date:  2011-12       Impact factor: 5.285

Review 5.  Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition?

Authors:  Karen Wager-Smith; Athina Markou
Journal:  Neurosci Biobehav Rev       Date:  2010-09-29       Impact factor: 8.989

6.  Effects of Tenofovir Combined with Recombinant Human Interferon α-2b on Negative Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.

Authors:  Hui Zhang; Jianchun Xian; Yang Li; Li Xiao; Lu Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-30       Impact factor: 2.650

Review 7.  Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder.

Authors:  Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2009-01       Impact factor: 6.186

8.  Risk factors for the development of depression in patients with hepatitis C taking interferon-α.

Authors:  Kimberley J Smith; Suzanne Norris; Cliona O'Farrelly; Shane M O'Mara
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-15       Impact factor: 2.570

9.  Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression.

Authors:  M Udina; R Navinés; E Egmond; G Oriolo; K Langohr; D Gimenez; M Valdés; E Gómez-Gil; I Grande; M Gratacós; F Kapczinski; F Artigas; E Vieta; R Solà; R Martín-Santos
Journal:  Int J Neuropsychopharmacol       Date:  2016-04-20       Impact factor: 5.176

10.  Development and Pilot-Testing of a Cognitive Behavioral Coping Skills Group Intervention for Patients with Chronic Hepatitis C.

Authors:  Donna M Evon; Carol E Golin; Rachel Ruffin; Michael W Fried
Journal:  Contemp Clin Trials Commun       Date:  2017-04-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.